Grover, Anita
Crippen-Harmon, Danielle
Nave, Lacey
Vincelette, Jon
Wait, Jill C. M.
Melton, Andrew C.
Lawrence, Roger
Brown, Jillian R.
Webster, Katherine A.
Yip, Bryan K.
Baridon, Brian
Vitelli, Catherine
Rigney, Sara
Christianson, Terri M.
Tiger, Pascale M. N.
Lo, Melanie J.
Holtzinger, John
Shaywitz, Adam J.
Crawford, Brett E.
Fitzpatrick, Paul A.
LeBowitz, Jonathan H.
Bullens, Sherry
Aoyagi-Scharber, Mika
Bunting, Stuart
O’Neill, Charles A.
Pinkstaff, Jason
Bagri, Anil
Funding for this research was provided by:
BioMarin Pharmaceutical
Article History
First Online: 15 January 2020
Compliance with ethical standards
:
: Danielle Crippen-Harmon, Jon Vincelette, Jill C. M. Wait, Andrew C. Melton, Roger Lawrence, Katherine A. Webster, Brian Baridon, Catherine Vitelli, Terri M. Christianson, Melanie J. Lo, John Holtzinger, Paul A. Fitzpatrick, Jonathan H. LeBowitz, Sherry Bullens, Stuart Bunting, Charles A. O’Neill, and Anil Bagri are employees and stockholders of BioMarin. Brett E. Crawford is an employee and stockholder of BioMarin and holds patents covering the NRE glycan analysis. Mika Aoyagi-Scharber is an employee and stockholder of BioMarin and holds a patent (US9376480B2) issued to BioMarin. Anita Grover, Lacey Nave, Jillian R. Brown, Bryan K. Yip, Sara Rigney, Adam J. Shaywitz, Pascale M. N. Tiger, and Jason Pinkstaff were employees of BioMarin when this study was conducted.
: All institutional and national guidelines for the care and use of laboratory animals were followed.